Ilka Wahl

Ilka Wahl

Auto-generated profile, based on publicly available information

Ilka Wahl

B Cell Immunology, German Cancer Research Center 1 , Heidelberg

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
UGUte Greczmiel
Ute Greczmiel
NKNike Julia Kräutler
Nike Julia Kräutler
APAlessandro Pedrioli
Alessandro Pedrioli
IBIlka Bartsch
Ilka Bartsch
PAPaola Agnellini
Paola Agnellini
AOAnnette Oxenius
Annette Oxenius
CXCR5 + T follicular helper cells promote generation of neutralizing antibodies in response to chronic viral infection.

24 October 2022 in Immunity
Verified
Journal Article
Closed access
IWIlka Wahl
Ilka Wahl
HWHedda Wardemann
Hedda Wardemann

10 January 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
IWIlka Wahl
Ilka Wahl
HWHedda Wardemann
Hedda Wardemann
The induction of protective humoral immune responses against sporozoite surface proteins of the human parasite Plasmodium falciparum (Pf) is a prime goal in the development of a preerythrocytic malaria vaccine. The most promising antibody target is circumsporozoite protein (CSP). Although PfCSP induces strong humoral immune responses upon vaccination, vaccine efficacy is overall limited and not durable. Here, we review recent efforts to gain a better molecular and cellular understanding of anti-PfCSP B cell responses in humans and discuss ways to overcome limitations in the induction of stable titers of high-affinity antibodies that might help to increase vaccine efficacy and promote long-lived protection.

24 June 2022 in Science Immunology
Verified
Journal Article
Closed access
IWIlka Wahl
Ilka Wahl
AOAnna S. Obraztsova
Anna S. Obraztsova
JPJulia Puchan
Julia Puchan
RHRebecca Hundsdorfer
Rebecca Hundsdorfer
SCSumana Chakravarty
Sumana Chakravarty
HWHedda Wardemann
Hedda Wardemann
T follicular helper (T FH ) cells play a crucial role in the development of long-lived, high-quality B cell responses after infection and vaccination. However, little is known about how antigen-specific T FH cells clonally evolve in response to complex pathogens and what guides the targeting of different epitopes. Here, we assessed the cell phenotype, clonal dynamics, and T cell receptor (TCR) specificity of human circulating T FH (cT FH ) cells during successive malaria immunizations with radiation-attenuated Plasmodium falciparum ( Pf ) sporozoites. Repeated parasite exposures induced a dynamic, polyclonal cT FH response with high frequency of cells specific to a small number of epitopes in Pf circumsporozoite protein (PfCSP), the primary sporozoite surface protein and well-defined vaccine target. Human leukocyte antigen (HLA) restrictions and differences in TCR generation probability were associated with differences in the epitope targeting frequency and indicated the potential of amino acids 311 to 333 in the Th2R/T* region as a T cell supertope. But most of vaccine-induced anti–amino acid 311 to 333 TCRs, including convergent TCRs with high sequence similarity, failed to tolerate natural polymorphisms in their target peptide sequence, thus demonstrating that the T FH cell response was limited to the vaccine strain. These data suggest that the high parasite diversity in endemic areas will limit boosting of the vaccine-induced T FH cell response by natural infections. Our findings may guide the further design of PfCSP-based malaria vaccines able to induce potent T helper cell responses for broad, long-lasting antibody responses.

10 July 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
HDHannah van Dijk
Hannah van Dijk
IWIlka Wahl
Ilka Wahl
SKSara Kraker
Sara Kraker
PRPaul M. Robben
Paul M. Robben
SDSheetij Dutta
Sheetij Dutta
HWHedda Wardemann
Hedda Wardemann
Plasmodium falciparum malaria remains a significant global health challenge. Current vaccines elicit antibody responses against circumsporozoite protein (PfCSP) that prevent the infection of hepatocytes but offer only moderate protection. Cellular immunity has emerged as a critical component of preerythrocytic protection that might be leveraged to develop improved PfCSP vaccines. Here, we characterized the clonality, molecular features, epitope specificity, and HLA restrictions of the human PfCSP-specific CD4+ and CD8+ T cell response to vaccination with an adjuvanted PfCSP vaccine, FMP013/ALFQ. Using TCR expression cloning, we identified novel conserved CD4+ T cell epitopes in the PfCSP N terminus and showed that the C-terminal CS.T3 epitope was targeted by CD4+ and rare CD8+ T cells, which recognized this epitope co-receptor independently presented on a class II HLA. Our findings provide insights into the utility of these epitopes as targets for strain-transcending immunity compared with the immunodominant but highly polymorphic epitopes in the PfCSP C terminus, offering guidance for the design of improved malaria vaccines.

11 September 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
IWIlka Wahl
Ilka Wahl
AOAnna Obraztsova
Anna Obraztsova
JPJulia Puchan
Julia Puchan
RHRebecca Hundsdorfer
Rebecca Hundsdorfer
SCSumana Chakravarty
Sumana Chakravarty
HWHedda Wardemann
Hedda Wardemann
T follicular helper (T FH ) cells play a crucial role in the development of long-lived, quality-improved B cell responses after infection and vaccination. However, little is known about their clonal evolution. Here we assessed the cell phenotype, clonal dynamics, and TCR specificity of human circulating T FH (cT FH ) cells at monoclonal level during successive malaria immunizations with radiation-attenuated Plasmodium falciparum ( Pf ) sporozoites. Repeated parasite exposures induced a dynamic, polyclonal cT FH response with high frequency of cells specific to the Pf circumsporozoite protein (PfCSP), the main surface protein of sporozoites and a validated vaccine target. Repeated immunizations were required to induce detectable PfCSP-reactive cT FH cell responses to a small number of epitopes. HLA-restrictions and differences in TCR generation probability explain the high targeting frequency of the polymorphic Th2R/T* region over the conserved T1 epitope. The vast majority of anti-Th2R/T* TCRs failed to tolerate natural polymorphisms in their target peptide sequence suggesting that parasite diversity limits natural boosting of the cT FH cell response in endemic areas and protection from non-vaccine strains. Among convergent anti-Th2R/T* TCRs with high sequence similarity, subtle differences in CDR3 composition discriminated cross-reactive from non-cross-reactive cT FH cells. Thus, our study provides deep molecular and cellular insights into the kinetics, fine specificity and HLA-restrictions of the anti-cT FH cell response that are of direct relevance for the design of PfCSP-based malaria vaccines by guiding the selection of PfCSP peptides that induce optimal B cell help.